Premium
Effect of oral omeprazole in reducing re‐bleeding in bleeding peptic ulcers: a prospective, double‐blind, randomized, clinical trial
Author(s) -
Kaviani M. J.,
Hashemi M. R.,
Kazemifar A. R.,
Roozitalab S.,
Mostaghni A.A.,
Merat S.,
AlizadehNaini M.,
Yarmohammadi H.
Publication year - 2003
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.2003.01416.x
Subject(s) - omeprazole , medicine , placebo , gastroenterology , peptic , randomized controlled trial , surgery , blood transfusion , peptic ulcer , alternative medicine , pathology
Summary Background : Endoscopic therapies and continuous intravenous omeprazole can decrease the morbidity and duration of hospital stay of patients with high‐risk peptic ulcer. Aim : To evaluate the role of oral omeprazole in high‐risk bleeders. Methods : After injection therapy of 160 patients with high‐risk peptic ulcer, 80 received oral omeprazole and 80 received placebo, and all were followed up. Results : One hundred and forty‐nine patients (71 omeprazole and 78 placebo) completed the study. Eleven patients were excluded from the study. Thirty‐seven (25%) patients had gastric ulcer and 112 (75%) had duodenal ulcer. Fifty‐seven (38%) ulcers showed visible vessels, 80 (54%) showed oozing of blood and 12 (8%) showed a spurting artery. Only one patient died (placebo group). The mean hospital stays were 62.8 ± 28.6 h and 75 ± 39 h in the omeprazole and placebo groups, respectively ( P = 0.032). The mean amounts of blood transfused were 1.13 ± 1.36 and 1.68 ± 1.68 bags in the omeprazole and placebo groups, respectively ( P = 0.029). The re‐bleeding rate was lower in the omeprazole group than in the placebo group (12 vs. 26, respectively; P = 0.022). Conclusion : Oral omeprazole is effective in decreasing the hospital stay, re‐bleeding rate and the need for blood transfusion in high‐risk ulcer bleeders treated with endoscopic injection therapy.